Your browser doesn't support javascript.
Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
Yin, Juntao; Chen, Yangyang; Li, Yang; Wang, Chaoyang; Zhang, Xingwang.
  • Yin J; Department of Pharmacy, Huaihe Hospital, Henan University, Henan, China. Electronic address: yinjuntao811@163.com.
  • Chen Y; Cardiology, Huaihe Hospital, Henan University, Henan, China. Electronic address: 45954356@qq.com.
  • Li Y; Department of Pharmacy, Huaihe Hospital, Henan University, Henan, China. Electronic address: hnsszyy0502@163.com.
  • Wang C; Institute of Evidence-based Medicine and Translational Medicine, Department of Medicine, Henan University, Henan, China. Electronic address: hyt0378@163.com.
  • Zhang X; Department of Pharmaceutics, School of Pharmacy, Jinan University, Guangdong, China. Electronic address: zhangxw@jnu.edu.cn.
Int J Infect Dis ; 124: 212-223, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2113251
ABSTRACT

OBJECTIVES:

Available data show that COVID-19 vaccines may be less effective in people living with HIV (PLWH) who are at increased risk for severe COVID-19. This meta-analysis aimed to compare the immunogenicity and efficacy of COVID-19 vaccines in PLWH with healthy individuals.

METHODS:

Pubmed/Medline, EMBASE, and the Cochrane Library were searched. Risk ratios of seroconversion were separately pooled using random-effects meta-analysis, and a systematic review without meta-analysis of SARS-CoV-2 antibody titer levels was performed after the first and second doses of a COVID-19 vaccine.

RESULTS:

A total of 22 studies with 6522 subjects met the inclusion criteria. After the first vaccine dose, seroconversion in PLWH was comparable to that in healthy individuals. After a second dose, seroconversion was slightly lower in PLWH compared with healthy controls, and antibody titers did not seem to be significantly affected or reduced among participants of both groups.

CONCLUSION:

COVID-19 vaccines show favorable immunogenicity and efficacy in PLWH. A second dose is associated with consistently improved seroconversion, although it is slightly lower in PLWH than in healthy individuals. Additional strategies, such as a booster vaccination with messenger RNA COVID-19 vaccines, might improve seroprotection for these patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article